Sharekhan's research report on Cipla
Promising growth outlook for Indian pharmaceutical markets (IPM), which is expected to grow in high single digit to low double digit for FY2022 coupled with Covid led opportunities (albeit in the near term) could benefit Cipla’s India business. Ramp up in gAlbuterol in US followed by a strong product pipeline of respiratory assets as well as complex generics would fuel the growth in US sales. Healthy topline growth, strong earnings visibility, and a healthy balance sheet augur well and would be key positives going ahead.
Outlook
We maintain Buy recommendation on Cipla Limited (Cipla) with a revised PT of Rs 1,100.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
